Bristol-Myers Squibb and BioNTech Forge $11.1 Billion Partnership to Revolutionize Cancer Treatment with BNT327
Bristol-Myers Squibb Co. has entered a strategic partnership with BioNTech to co-develop and co-commercialize BNT327, a promising bispecific antibody candidate for treating multiple solid tumor types.
2 minutes to read